Revolutionizing the treatment of neuropsychiatric disorders
- Brandaris Therapeutics is a translational stage biotech pioneering a new frontier in neuroscience and the treatment of neuropsychiatric disorders
- Our innovative approach is transforming the way we understand and treat conditions such as depression and anxiety disorders
- Taking a new and disruptive approach to classical receptor pharmacology, Brandaris is developing targeted therapies with a differentiated mechanism of action
- Our molecules are anticipated to deliver marked, rapid-onset and durable efficacy with favourable side effect profiles
Unmet medical need
- 1 in every 8 people in the world live with a neuropsychiatric disorder¹
- Despite current treatment options, millions of patients experience inadequate relief and debilitating side-effects
- Brandaris is addressing this gap with novel therapeutics that offer a shining light for those living with mental health disorders
¹World Health Organisation – Mental Health Atlas 2020
Our Approach
Our portfolio consists of first-in-class and best-in-class drug candidates, backed by strong preclinical and translational data, demonstrating transformative potential and offering groundbreaking treatments for the millions that suffer from neuropsychiatric disorders.
Team
Our team comprises leading neuroscientists, biotech innovators and pharmaceutical industry experts dedicated to pushing the boundaries of medical innovation.
Investors
Contact us
Brandaris Therapeutics B.V.
Galileiweg 8
2333 BD Leiden
The Netherlands
E-mail: info@brandaristx.com